ItoY, MiyauchiA, KiharaM, HigashiyamaT, KobayashiK, MiyaA. 2013. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid, 24:27–34.
2.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
3.
XingM, LiuR, LiuX, MuruganAK, ZhuG, ZeigerMA, PaiS, BishopJ. 2014. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol, 32:2718–2726.
4.
MatsuseM, YabutaT, SaenkoV, HirokawaM, NishiharaE, SuzukiK, YamashitaS, MiyauchiA, MitsutakeN. 2017. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci Rep, 7:41752.
5.
HirokawaM, KudoT, OtaH, SuzukiA, MiyauchiA. 2016. Pathological characteristics of low-risk papillary thyroid microcarcinoma with progression during active surveillance. Endocr J, 63:805–810.
